SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-029969
Filing Date
2024-03-01
Accepted
2024-03-01 16:10:02
Documents
20
Period of Report
2024-02-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm247553d1_8k.htm   iXBRL 8-K 32737
2 EXHIBIT 1.1 tm247553d1_ex1-1.htm EX-1.1 293165
3 EXHIBIT 5.1 tm247553d1_ex5-1.htm EX-5.1 7798
4 EXHIBIT 99.1 tm247553d1_ex99-1.htm EX-99.1 9489
5 EXHIBIT 99.2 tm247553d1_ex99-2.htm EX-99.2 10060
9 GRAPHIC tm247553d1_ex99-1img01.jpg GRAPHIC 3070
10 GRAPHIC tm247553d1_ex99-2img001.jpg GRAPHIC 8252
  Complete submission text file 0001104659-24-029969.txt   625595

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA cldx-20240228.xsd EX-101.SCH 3048
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20240228_lab.xml EX-101.LAB 34240
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20240228_pre.xml EX-101.PRE 22381
21 EXTRACTED XBRL INSTANCE DOCUMENT tm247553d1_8k_htm.xml XML 3530
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 24709756
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)